Sean E. Mcguire

Radiation Oncology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer.

Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer.

Journal: CA: a cancer journal for clinicians

Published: March 31, 2026

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

Journal: JNCI cancer spectrum

Published: March 16, 2026

Hyaluronic Acid Rectal Wall Infiltration and Reversal in Patients With Prostate Cancer Undergoing Radiation Therapy-A Case Series.

Hyaluronic Acid Rectal Wall Infiltration and Reversal in Patients With Prostate Cancer Undergoing Radiation Therapy-A Case Series.

Journal: Advances in radiation oncology

Published: August 14, 2025

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 14, 2025

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

Journal: European urology

Published: January 07, 2025

Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancer.

Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancer.

Journal: Brachytherapy

Published: September 15, 2024

Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences.

Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences.

Journal: Brachytherapy

Published: July 17, 2024

Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.

Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.

Journal: Clinical and translational radiation oncology

Published: June 06, 2024

Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center.

Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center.

Journal: Clinical and translational radiation oncology

Published: May 17, 2024

Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.

Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.

Journal: International journal of radiation oncology, biology, physics

Published: October 16, 2023

Definitive local therapy for T4 prostate cancer associated with improved local control and survival.

Definitive local therapy for T4 prostate cancer associated with improved local control and survival.

Journal: BJU international

Published: April 14, 2023

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: April 06, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026